FGF23 and X-linked hypophosphatemia: Furthermore, a preclinical study showed that treatment with a FGF23 antibody (Amgen) in Hyp mice had limited benefits on oral features.23 Therefore, the impact of burosumab on dento-alveolar tissues is still matter of debate whereas this therapy is nowadays frequently prescribed.12,24,25 Here, we aimed to determine whether FGF23 antibody (FGF23-mAb) therapy improved the dental features associated with XLH in young Hyp mice.